In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies

Stem Cells and Development

Volumn 22, Issue 7, 2013, Pages 1007-1015

  Farag, Sherif S ^a   Srivastava, Shivani ^a   Messina Graham, Steven ^a   Schwartz, Jennifer ^a   Robertson, Michael J ^a   Abonour, Rafat ^a   Cornetta, Kenneth ^a   Wood, Lisa ^a   Secrest, Angie ^a   Strother, R Matthew ^a   Jones, David R ^a   Broxmeyer, Hal E ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DIPEPTIDYL PEPTIDASE IV; FLUDARABINE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SITAGLIPTIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE CHOLECYSTITIS; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADENOVIRUS; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CORD BLOOD STEM CELL TRANSPLANTATION; DIARRHEA; DRUG BLOOD LEVEL; ENGRAFTMENT; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HLA SYSTEM; HUMAN; HUMAN HERPESVIRUS 6; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; IN VIVO STUDY; INFECTIOUS COMPLICATION; KLEBSIELLA PNEUMONIAE INFECTION; LIQUID LIQUID EXTRACTION; LIVER VENOOCCLUSIVE DISEASE; LUNG ASPERGILLOSIS; MALE; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; ORAL MUCOSITIS; OVERALL SURVIVAL; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; RADIATION DOSE; SEPSIS; SEPTICEMIA; STAPHYLOCOCCAL PNEUMONIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TOXOPLASMOSIS; VOMITING; WHOLE BODY RADIATION;

ADULT; CORD BLOOD STEM CELL TRANSPLANTATION; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; FETAL BLOOD; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PYRAZINES; TRANSPLANTATION CONDITIONING; TRIAZOLES; YOUNG ADULT;

MURINAE;

EID: 84875956072     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0636     Document Type: Article

References (46)

1. Broxmeyer HE and FO Smith. (2009). Cord blood hematopoietic cell transplantation. In: Thomas' Hematopoietic Cell Transplantation, 4th Edition. Appelbaum FR, SJ Forman, RS Negrin and KG Blume, eds. Wiley Blackwell, Malden, MA, pp 559-575.
2. Barker JN, DJ Weisdorf, TE DeFor, BR Blazar, PB McGlave, JS Miller, CM Verfaillie and JE Wagner. (2005). Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 105:1343-1347.
3. Rocha V, A Crotta, A Ruggeri, D Purtill, K Boudjedir, AL Herr, I Ionescu and E Gluckman. (2010). Double cord blood transplantation: extending the use of unrelated umbilical cord blood cells for patients with hematological diseases. Best Pract Res Clin Haematol 23:223-229.
4. Delaney C, S Heimfeld, C Brashem-Stein, H Voorhies, RL Manger and ID Bernstein. (2010). Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 16:232-236.
5. Bautista G, JR Cabrera, C Regidor, R Fores, JA Garcia-Marco, E Ojeda, I Sanjuan, E Ruiz, I Krsnik, et al. (2009). Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor. Bone Marrow Transplant 43:365-373.
6. Liu H, ES Rich, L Godley, O Odenike, L Joseph, S Marino, J Kline, V Nguyen, J Cunningham, et al. (2011). Reducedintensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood 118:6438-6445.
7. Peled A, I Petit, O Kollet, M Magid, T Ponomaryov, T Byk, A Nagler, H Ben-Hur, A Many, et al. (1999). Dependence of human stem cell engraftment and repopulation of NOD/ SCID mice on CXCR4. Science 283:845-848.
8. Broxmeyer HE, S Cooper, L Kohli, G Hangoc, Y Lee, C Mantel, DW Clapp and CH Kim. (2003). Transgenic expression of stromal cell-derived factor-1/CXC chemokine ligand 12 enhances myeloid progenitor cell survival/ antiapoptosis in vitro in response to growth factor withdrawal and enhances myelopoiesis in vivo. J Immunol 170:421-429.
9. Christopherson KW, 2nd, G Hangoc and HE Broxmeyer. (2002). Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alphamediated chemotaxis of human cord blood CD34 + progenitor cells. J Immunol 169:7000-7008.
10. Christopherson KW, 2nd, G Hangoc, CR Mantel and HE Broxmeyer. (2004). Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 305:1000-1003.
11. Durinx C, AM Lambeir, E Bosmans, JB Falmagne, R Berghmans, A Haemers, S Scharpe and I De Meester. (2000). Molecular characterization ofdipeptidylpeptidase activity in serum: soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides. Eur J Biochem 267:5608-5613.
12. Mentlein R. (1999). Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85:9-24.
13. Campbell TB, G Hangoc, Y Liu, K Pollok and HE Broxmeyer. (2007). Inhibition of CD26 in human cord blood CD34 + cells enhances their engraftment of nonobese diabetic/ severe combined immunodeficiency mice. Stem Cells Dev 16:347-354.
14. Christopherson KW, 2nd, LA Paganessi, S Napier and NK Porecha. (2007). CD26 inhibition on CD34 + or lineage- human umbilical cord blood donor hematopoietic stem cells/ hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev 16:355-360.
15. Kawai T, U Choi, PC Liu, NL Whiting-Theobald, GF Linton and HL Malech. (2007). Diprotin A infusion into nonobese diabetic/severe combined immunodeficiency mice markedly enhances engraftment of human mobilized CD34 + peripheral blood cells. Stem Cells Dev 16:361-370.
16. Broxmeyer HE, G Hangoc, S Cooper, T Campbell, S Ito and C Mantel. (2007). AMD3100 and CD26 modulate mobilization, engraftment, and survival of hematopoietic stem and progenitor cells mediated by the SDF-1/CXCL12-CXCR4 axis. Ann N Y Acad Sci 1106:1-19.
17. Campbell TB and HE Broxmeyer. (2008). CD26 inhibition and hematopoiesis: a novel approach to enhance transplantation. Front Biosci 13:1795-1805.
18. Broxmeyer HE, J Hoggatt, HA O'Leary, C Mantel, BR Chitteti, S Cooper, S Messina-Graham, G Hangoc, SS Farag, et al. (2012). Dipeptidylpeptidase 4 negatively regulates colony stimulating factor activity and stress hematopoiesis. Nat Med 18:1786-1796.
19. Rubinstein P, L Dobrila, RE Rosenfield, JW Adamson, G Migliaccio, AR Migliaccio, PE Taylor and CE Stevens. (1995). Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci U S A 92:10119-10122.
20. Cutler C, HT Kim, E Hochberg, V Ho, E Alyea, SJ Lee, DC Fisher, D Miklos, J Levin, et al. (2004). Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10:328-336.
21. Bergman AJ, C Stevens, Y Zhou, B Yi, M Laethem, M De Smet, K Snyder, D Hilliard, W Tanaka, et al. (2006). Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28:55-72.
22. Nakamura Y, M Leppert, P O'Connell, R Wolff, T Holm, M Culver, C Martin, E Fujimoto, M Hoff, et al. (1987). Variable number of tandem repeat (VNTR) markers for human gene mapping. Science 235:1616-1622.
23. Atkinson K, MM Horowitz, RP Gale, MB Lee, AA Rimm and MM Bortin. (1989). Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Committee of the International Bone Marrow Transplant Registry. Bone Marrow Transplant 4:247-254.
24. Przepiorka D, D Weisdorf, P Martin, HG Klingemann, P Beatty, J Hows and ED Thomas. (1995). 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825-828.
25. Kaplan EL and P Meier. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481.
26. Barker JN, A Scaradavou and CE Stevens. (2010). Combined effect of total nucleated cell dose and HLA match on transplantation outcome in 1061 cord blood recipients with hematologic malignancies. Blood 115:1843-1849.
27. Sanz J, JC Boluda, C Martin, M Gonzalez, C Ferra, D Serrano, CD de Heredia, C Barrenetxea, AM Martinez, et al. (2012). Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 47:1287-1293.
28. Page KM, L Zhang, A Mendizabal, S Wease, S Carter, T Gentry, AE Balber and J Kurtzberg. (2011). Total colonyforming units are a strong, independent predictor of neutrophil and platelet engraftment after unrelated umbilical cord blood transplantation: a single-center analysis of 435 cord blood transplants. Biol Blood Marrow Transplant 17:1362-1374.
29. Gluckman E, V Rocha, A Boyer-Chammard, F Locatelli, W Arcese, R Pasquini, J Ortega, G Souillet, E Ferreira, et al. (1997). Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med 337:373-381.
30. Rubinstein P, C Carrier, A Scaradavou, J Kurtzberg, J Adamson, AR Migliaccio, RL Berkowitz, M Cabbad, NL Dobrila, et al. (1998). Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 339:1565-1577.
31. Wagner JE, JN Barker, TE DeFor, KS Baker, BR Blazar, C Eide, A Goldman, J Kersey, W Krivit, et al. (2002). Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatmentrelated mortality and survival. Blood 100:1611-1618.
32. Laughlin MJ, J Barker, B Bambach, ON Koc, DA Rizzieri, JE Wagner, SL Gerson, HM Lazarus, M Cairo, et al. (2001). Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med 344:1815-1822.
33. Barker JN. (2007). Who should get cord blood transplants? Biol Blood Marrow Transplant 13:78-82.
34. Rosenstock J and B Zinman. (2007). Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 14:98-107.
35. Rocha V, M Labopin, G Sanz, W Arcese, R Schwerdtfeger, A Bosi, N Jacobsen, T Ruutu, M de Lima, et al. (2004). Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 351:2276-2285.
36. Laughlin MJ, M Eapen, P Rubinstein, JE Wagner, MJ Zhang, RE Champlin, C Stevens, JN Barker, RP Gale, et al. (2004). Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 351:2265-2275.
37. Takahashi S, J Ooi, A Tomonari, T Konuma, N Tsukada, M Oiwa-Monna, K Fukuno, M Uchiyama, K Takasugi, et al. (2007). Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood 109:1322-1330.
38. Eapen M, V Rocha, G Sanz, A Scaradavou, MJ Zhang, W Arcese, A Sirvent, RE Champlin, N Chao, et al., Center for International, R Marrow Transplant, E Acute Leukemia Working Party and C National Cord Blood Program of the New York Blood. (2010). Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol 11:653-660.
39. Brunstein CG, JA Gutman, DJ Weisdorf, AE Woolfrey, TE Defor, TA Gooley, MR Verneris, FR Appelbaum, JE Wagner and C Delaney. (2010). Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 116:4693-4699.
40. Chow R, A Nademanee, J Rosenthal, C Karanes, TH Jaing, ML Graham, E Tsukahara, B Wang, D Gjertson, et al. (2007). Analysis of hematopoietic cell transplants using plasmadepleted cord blood products that are not red blood cell reduced. Biol Blood Marrow Transplant 13:1346-1357.
41. Rocha V and HE Broxmeyer. (2010). New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant 16:S126-S132.
42. Kindwall-Keller TL, Y Hegerfeldt, HJ Meyerson, S Margevicius, P Fu,Wvan Heeckeren, HM Lazarus, BW Cooper, SL Gerson, et al. (2012). Prospective study of one- vs two-unit umbilical cord blood transplantation following reduced intensity conditioning in adults with hematological malignancies. Bone Marrow Transplant 47:924-933.
43. Frassoni F, F Gualandi, M Podesta, AM Raiola, A Ibatici, G Piaggio, M Sessarego, N Sessarego, M Gobbi, et al. (2008). Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncol 9:831-839.
44. Robinson SN, PJ Simmons, MW Thomas, N Brouard, JA Javni, S Trilok, JS Shim, H Yang, D Steiner, et al. (2012). Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Exp Hematol 40: 445-456.
45. Hoggatt J, P Singh, J Sampath and LM Pelus. (2009). Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 113:5444-5455.
46. Goessling W, RS Allen, X Guan, P Jin, N Uchida, M Dovey, JM Harris, ME Metzger, AC Bonifacino, et al. (2011). Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 8: 445-458.